GSK2118436

PreclinicalSmall molecule

GSK

GSK2118436 is one of 8 small molecule programs targeting Papillary Thyroid Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Papillary Thyroid CarcinomaActive, not recruiting

Papillary Thyroid CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Papillary Thyroid Carcinoma

#DrugCompanyPhaseTrials

Gleevec

Istodax

Retevmo

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Thyroxine

WWashington University School of Medicine

Phase 2

1 6

Tafinlar

Alcohol

GSK2118436

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Solid Tumors5 trials

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00880321·170 enrolled

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01582997·12 enrolled

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01340846·48 enrolled

Show 2 more trials

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01340833·6 enrolled

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01262963·4 enrolled

Metastatic Melanoma3 trials

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Completed· GSK logo

GSK·Phase 2·NCT01266967·172 enrolled

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01619774·28 enrolled

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Completed· GSK logo

GSK·Phase 2·NCT01153763·92 enrolled

Treatment1 trial

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT01231594·214 enrolled

Melanoma1 trial

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Completed· GSK logo

GSK·Phase 3·NCT01227889·251 enrolled

Tics1 trial

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Completed· Novartis logo

Novartis·Phase 2·NCT01072175·430 enrolled

2 more indications

Cardiac Repolarization1 trial

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Completed· GSK logo

GSK·Phase 1·NCT01738451·50 enrolled

Papillary Thyroid Carcinoma1 trial

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Completed·MMassachusetts General Hospital·N/A·NCT01534897·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for GSK2118436. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK2118436 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK2118436. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

GSK2118436

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Solid Tumors5 trials

Metastatic Melanoma3 trials

Treatment1 trial

Melanoma1 trial

Tics1 trial

Cardiac Repolarization1 trial

Papillary Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News